Benign Prostatic Hyperplasia Bph And Prostate Treatment Market

Benign Prostatic Hyperplasia (BPH) Prostate Treatment Market: Innovations in Non-invasive Treatment Alternatives to Provide Strong Impetus: Global Industry Analysis 2013-2017 and Opportunity Assessment 2018-2028

  • 2019-03-06
  • REP-GB-1664
  • 32 Tables
  • 121 Figures
  • 252 pages
  • PDF PPT EXCEL
Benign Prostatic Hyperplasia Bph And Prostate Treatment Market

An Incisive, In-depth Analysis on the Benign Prostatic Hyperplasia Bph And Prostate Treatment Market

This study offers a comprehensive, 360 degree analysis on the Benign Prostatic Hyperplasia Bph And Prostate Treatment market, bringing to fore insights that can help stakeholders identify the opportunities as well as challenges. It tracks the global Benign Prostatic Hyperplasia Bph And Prostate Treatment market across key regions, and offers in-depth commentary and accurate quantitative insights. The study also includes incisive competitive landscape analysis, and provides key recommendations to market players on winning imperatives and successful strategies.

Prevalence of Benign Prostatic Hyperplasia Is on a Steady Rise 

According to the recent statistical data,

  • In the US, more than 8 million men are suffering from benign prostatic hyperplasia.

  • Globally, around 22 million men have been diagnosed with moderate-to-severe symptoms of benign prostatic hyperplasia.

  • The risk of having benign prostatic hyperplasia increases after the age of 40 by around 8%, and by the age of 90, the risk increases by as much as 60%.

The rising prevalence of benign prostatic hyperplasia (BPH) is the key factor driving the growth of the benign prostatic hyperplasia prostate treatment market. A few other factors such as diet, heredity, and lifestyle also play an important role in causing benign prostatic hyperplasia. With the increasingly aging population and a changing demographic profile in almost all societies, it is expected that benign prostatic hyperplasia prostate treatment will become a major challenge for all healthcare systems, and even more prevalent among men during the forecast period.

Nearly 50% men across the world by the age of 50 years and above are suffering from the medical condition – benign prostatic hyperplasia (BPH) prostate, according to a study published in the Canadian Journal of Urology. Stakeholders in the benign prostatic hyperplasia prostate treatment market are aiming to bolster their research & development activities to improve the efficacy of the existing medications. Thereby, the global market for benign prostatic hyperplasia prostate treatment is expected to witness steady growth, reaching US$ 25 billion in the coming decade.

Preeminent factors that are influencing the growth of the benign prostatic hyperplasia prostate treatment market include:

Advancements in Management of Benign Prostatic Hyperplasia

In the future, the demand for benign prostatic hyperplasia prostate treatment is expected to witness strong growth. Currently, a number of novel techniques are under clinical trials. Technology has played an important role in the latest advances in the management of benign prostatic hyperplasia prostate treatment.

Recently, a prostatic urethral lift has been considered to be one of the most favorable new techniques that have been performed in benign prostatic hyperplasia prostate treatment. In this technique, a novel mechanical implant is placed into the prostate by pulling the encroaching lobes of the prostate and improves a man’s urine flow.

Alpha-blockers are the first-line treatment that relaxes the prostate smooth muscle fibers. Excluding traditional oral solid dosage pharmaceuticals, many studies have been carried out using injectable drug delivery systems directly into the prostate. This has been stimulated by the increased use and efficiency of Botox treatment in the bladder. These initial trials of intraprostatic injections are expected to hold a promising influence on the overall development of benign prostatic hyperplasia prostate treatment market.

Mounting Costs of Benign Prostatic Hyperplasia Treatment

Financing healthcare costs due to the rising demand for benign prostatic hyperplasia prostate treatment is a great challenge. Basically, benign prostatic hyperplasia prostate treatment depends upon the severity of the condition and may involve pharmacotherapy and a number of surgical procedures. Hence, benign prostatic hyperplasia prostate treatment costs may vary dramatically. The latest UroLift System treatment is similar in effectiveness but costs twice as much as compared to other prostatic hyperplasia prostate treatments.

Economical and minimally invasive therapies are available options to patients, and are slightly more expensive than the combination of drug therapy and generic drugs. In the US, a few years ago, annual direct and indirect costs to the private sector associated with benign prostatic hyperplasia treatment were estimated to be US$ 4 Bn. It has been observed that the costs tend to spike with the increasing number of aging men who are suffering from benign prostatic hyperplasia. High price point associated with the benign prostatic hyperplasia prostate treatment will continue to limit market growth in the long run.

Competition Analysis

The competitive landscape of benign prostatic hyperplasia prostate treatment market involves some of the industry behemoths, posing strong competition facing other smaller players. The report covers Pfizer, Inc., Valeant Pharmaceuticals Inc., Novartis AG, Bayer AG, Sanofi S.A., GlaxoSmithKline plc., Bristol-Myers Squibb and Company, Teva Pharmaceutical Industries Ltd, Mylan N.V., Merck & Co., Cardinal Health Inc., and Eli Lilly and Company among others.  

Definition

Benign prostatic hyperplasia prostate treatment includes a wide range of drugs and devices used for benign prostatic hyperplasia conditions. Drug-based therapy is the first line of treatment used widely for benign prostatic hyperplasia prostate treatment.

About the Report

The company conducted a research study on the benign prostatic hyperplasia prostate treatment market for the forecast period 2018 to 2028. This report provides a thorough assessment of opportunities in the benign prostatic hyperplasia prostate treatment market and provides an understanding of benign prostatic hyperplasia conditions, and lower urinary tract infections, and awareness level of benign prostatic hyperplasia prostate treatment and market competition in the benign prostatic hyperplasia prostate treatment market. The report provides thorough information regarding macroeconomic factors affecting the growth of the benign prostatic hyperplasia prostate treatment market.

Segmentation

The report offers a wide-ranging taxonomy of the benign prostatic hyperplasia prostate treatment market. The benign prostatic hyperplasia prostate treatment market has been segmented on the basis of treatment type, distribution channel, and region. The benign prostatic hyperplasia prostate treatment market has been segmented by treatment type into alpha-blockers, -alpha reductase inhibitors, phosphodiesterase-5 (PDE-5) Inhibitors, muscarinic receptor antagonist, and combination drugs. By distribution channel, the benign prostatic hyperplasia prostate treatment market has been segmented into institutional sales, retail sales, and online pharmacies.

Additional Questions Answered

Additional questions addressed in this benign prostatic hyperplasia prostate treatment market report are:

  • What is the revenue potential of the benign prostatic hyperplasia prostate treatment market across North America and Europe?

  • Who are the key players and what are their product portfolios in the benign prostatic hyperplasia prostate treatment market?

  • What are the major challenges impacting the growth of the benign prostatic hyperplasia prostate treatment market?

  • How is the involvement from key regulatory bodies shaping the growth of the benign prostatic hyperplasia prostate treatment market?

Research Methodology

The benign prostatic hyperplasia prostate treatment market has been estimated based on a supply-demand approach. The benign prostatic hyperplasia prostate treatment market was first studied based on the prevalence of benign prostatic hyperplasia conditions, diagnosis and treatment rate and availability of the drug in the different distribution channels across different regions/countries.

Further, qualitative factors impacting the benign prostatic hyperplasia prostate treatment market, such as awareness regarding benign prostatic hyperplasia prostate treatment and availability of drugs, average prices of drugs, key regulations and others, were studied.

Data analysis was validated through primary research methods, such as telephonic interviews, in-person interactions, surveys and viewpoints of experienced analysts & secondary research resources, such as trade journals, databases and verified paid sources. The research study on the benign prostatic hyperplasia prostate treatment market also provides the top trends and macro- and microeconomic factors influencing the benign prostatic hyperplasia prostate treatment market.

The company’s recent market study titled 'Benign Prostatic Hyperplasia Prostate Treatment Market: Global Industry Analysis 2013-2017 & Opportunity Assessment 2018-2028' comprises a comprehensive assessment of the key market dynamics. Through detailed research on the growth parameters of the benign prostatic hyperplasia prostate treatment market, growth forecasts of the market have been obtained with maximum accuracy.

The report features exclusive and significant factors that have a huge impact on the development of the benign prostatic hyperplasia prostate treatment market during the forecast period. These factors can aid market players in developing marketing and manufacturing strategies, and visualize maximum growth in the benign prostatic hyperplasia prostate treatment market during the forecast years. The report offers thorough information about the growth prospects of the benign prostatic hyperplasia prostate treatment market in a comprehensive way for a better understanding of readers.

Chapter 1 – Executive Summary

The report begins with the executive summary of the benign prostatic hyperplasia prostate treatment market, which includes a detailed summary of the key findings, statistics, and technology roadmap of the market. It also includes the market value (US$ million) estimations of leading segments in the benign prostatic hyperplasia prostate treatment market.

Chapter 2 – Market Introduction and Overview

The report summaries the detailed taxonomy and definitions, which are key to understanding the basic information regarding the benign prostatic hyperplasia prostate treatment market dynamics, key players, pricing analysis, and regulation policies of this market.

Chapter 3 – Global Benign Prostatic Hyperplasia Prostate Treatment Market Analysis 2013-2017 & Opportunity Assessment 2018-2028 by Treatment Type

Based on treatment type, the benign prostatic hyperplasia prostate treatment market has been segmented into drugs and devices. The drugs segment of the benign prostatic hyperplasia prostate treatment market is segmented into alpha-blockers, alpha reductase inhibitors, phosphodiesterase-5 (PDE-5) inhibitors, muscarinic receptor antagonists, and combination drugs. The devices segment in the benign prostatic hyperplasia prostate treatment market is segmented into prostatic stents, suture base implant systems, and transurethral RF thermal therapy. Readers can find detailed information regarding the key market trends, developments, and market attractive analysis of the benign prostatic hyperplasia prostate treatment market based on treatment type.

Chapter 4 – Global Benign Prostatic Hyperplasia Prostate Treatment Market Analysis 2013-2017 & Opportunity Assessment 2018-2028 by Distribution Channel

In terms of the distribution channel, the benign prostatic hyperplasia prostate treatment market is segmented into institutional sales, retail sales, and online pharmacies. Further, the institutional sales segment is sub-segmented into hospitals, ambulatory surgical centers, and specialty clinics. The retail sales segment is sub-segmented into retail pharmacies and drug stores.

Chapter 5 – Global Benign Prostatic Hyperplasia Prostate Treatment Market Analysis 2013-2017 & Opportunity Assessment 2018-2028 by Region

This chapter provides detailed information regarding the current growth scenario of the benign prostatic hyperplasia prostate treatment market across various geographic regions such as North America, Latin America, Europe, South Asia, East Asia, Oceania, and the Middle East & Africa (MEA).

Chapter 6 – North America Benign Prostatic Hyperplasia Prostate Treatment Market Analysis 2013-2017 & Opportunity Assessment 2018-2028

This chapter includes a detailed analysis of the North America benign prostatic hyperplasia prostate treatment market growth, along with a country-wise assessment, including the U.S. and Canada. Readers can find detailed information regarding regional trends, macroeconomic factors, and market growth based on treatment type, distribution channel, and country, in the North America benign prostatic hyperplasia prostate treatment market.

Chapter 7 – Latin America Benign Prostatic Hyperplasia Prostate Treatment Market Analysis 2013-2017 & Opportunity Assessment 2018-2028

This chapter consists of the growth forecasts for the Latin America benign prostatic hyperplasia prostate treatment market in leading countries such as Brazil, Mexico, and the Rest of Latin America. Readers can also find detailed information regarding factors such as pricing analysis, regional trends, and growth factors that are influencing the growth of the Latin America benign prostatic hyperplasia prostate treatment market.

Chapter 8 – Europe Benign Prostatic Hyperplasia Prostate Treatment Market Analysis 2013-2017 & Opportunity Assessment 2018-2028

In this chapter, readers can find detailed information regarding key growth forecasts of the benign prostatic hyperplasia prostate treatment market based on applications in various European countries such as the U.K., Germany, France, Italy, Spain, Russia, and the Rest of Europe.

Chapter 9 – South Asia Benign Prostatic Hyperplasia Prostate Treatment Market Analysis 2013-2017 & Opportunity Assessment 2018-2028

This chapter includes the growth prospects of the benign prostatic hyperplasia prostate treatment market in leading South Asian countries such as India, Thailand, Indonesia, Malaysia, and the Rest of South Asia.

Chapter 10 – East Asia Benign Prostatic Hyperplasia Prostate Treatment Market Analysis 2013-2017 & Opportunity Assessment 2018-2028

This chapter includes the growth prospects of the benign prostatic hyperplasia prostate treatment market in leading East Asian countries such as China, Japan, and South Korea.

Chapter 11 – Oceania Benign Prostatic Hyperplasia Prostate Treatment Market Analysis 2013-2017 & Opportunity Assessment 2018-2028

In this chapter, readers can find detailed information regarding several parameters influencing the Oceania benign prostatic hyperplasia prostate treatment market during the forecast period 2018-2028. Australia and New Zealand are the leading countries in Oceania that are the prime subjects of assessment to obtain the growth prospects of the Oceania benign prostatic hyperplasia prostate treatment market.

Chapter 12 – MEA Benign Prostatic Hyperplasia Prostate Treatment Market Analysis 2013-2017 & Opportunity Assessment 2018-2028

Readers can find thorough information regarding the growth factors that are impacting the MEA benign prostatic hyperplasia prostate treatment market, and gain insights on how the benign prostatic hyperplasia prostate treatment market is likely to impact the main countries/region in MEA, such as GCC Countries, Turkey, North Africa, South Africa, and the Rest of MEA, over the forecast period 2018-2028.

Chapter 13 – Competition Landscape, Company Share, and Company Profiles

This chapter provides readers a wide-ranging list of all the prominent key players in the benign prostatic hyperplasia prostate treatment market, along with detailed information regarding each company, including company overview, offered products, revenue shares, key strategy, and recent company developments.

Chapter 14 – Assumptions and Acronyms

This chapter in the benign prostatic hyperplasia prostate treatment market report includes a list of assumptions and acronyms that provide a base to the statistics and information included in the report.

Chapter 15 – Research Methodology

This chapter in the benign prostatic hyperplasia prostate treatment market report provides readers with a detailed research methodology employed to obtain various conclusions and important qualitative and quantitative information regarding the benign prostatic hyperplasia prostate treatment market.

Benign Prostatic Hyperplasia Bph And Prostate Treatment Market Reports - Table of Contents

Get in touch

Harish Tiwari

Harish Tiwari

Global Head - Business Development

Pranay Mhaisekar

Pranay Mhaisekar

Business Development

* indicates mandatory fields.

Our Clients


CASE STUDIES

See how our work makes an impact.

At FMI, we design strategies that are adaptive, impactful, and implementable.

Request Sample Ask An Analyst Request Special Price Request Methodology